Abstract

The platform will initially have libraries of FDA approved compounds and fragment libraries available for researchers, and ill be in charge of growing the number and diversity of compound libraries available for screening assays, through the purchase of new commercial libraries, libraries from drug discovery centers that have freely under‐request libraries (e.g. NCI/NIH, USA) or accessible libraries under standard compliances (e.g. EU Openscreen); molecule libraries from pharmaceutical companies (e.g. Astrazeneca openinnovation, GSK) and also local compounds or natural extract libraries to generate in the future the first national repository of small molecule libraries stored under industry GLP‐like standards. To continuously support intra and inter‐institutional collaborative research we will invite researchers to join to a Collaborative Drug Discovery and Therapeutic Innovation Network to generate associative and synergic instances to exchange knowledge, expertise and specialized advice for drug discovery and development projects. We will also integrate into this network consultants and researchers from pharma biotech startups dedicated to therapeutic innovation. This network will operate in part through a collaborative non‐hierarchical online community hosted in the platform web site to allow researchers to contribute and collaborate freely around various drug development programs. We will also integrate to this platform, technology managers and drug IP specialist for advice in technology roadmaps, regulatory framework analysis and intellectual property analysis. We will maintain high standards of record-keeping and confidentiality of sensitive information that may be subject to intellectual property through utilizing the scientific data management system & ELN software CDD Vault hile maintaining an open science policy to the extent that it does not affect IP, for example, compound libraries database, screening protocols and molecular or cell‐based tools for performing screening assays.